Eikon Therapeutics pricing
No platform price exists because the imaging platform is capital intensive instrumentation operated in house and is not licensed to anyone; the commercial surface is the company's own pipeline. The capital history is well documented: more than $1 billion raised privately since the 2019 founding, including a $517 million Series B in 2022 and a Series D of roughly $351 million, followed by a Nasdaq listing under EIKN in a February 2026 offering reported at $381 million, with a registration statement on file.
How Eikon Therapeutics pricing works
- Pricing model
- Own pipeline, combining platform originated preclinical programs with acquired and in licensed clinical assets. No platform access is sold.
One commercial fact is easy to miss and changes how the company reads as a technology: a meaningful share of that capital has gone into acquiring and in licensing clinical assets rather than advancing platform originated ones, with the lead candidate acquired from a partner and two PARP inhibitors licensed in. What the platform has produced on its own, and what stage those programs have reached, is not set out.
Eikon Therapeutics pricing against its alternatives
Published prices for Eikon Therapeutics and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- EEikon TherapeuticsNot applicable
- RRecursionNot applicable
- VVerge LabsPartnership structured, no list pricing
- IinsitroNot applicable
- EEarendil LabsNo published price
- SSuperluminal MedicinesNo published price
- RRelay TherapeuticsNot applicable
- CCellarityNot applicable
- XXaira TherapeuticsNot applicable
Eikon Therapeutics pricing, answered
How much does Eikon Therapeutics cost?
Eikon Therapeutics does not publish a price. No platform price exists because the imaging platform is capital intensive instrumentation operated in house and is not licensed to anyone; the commercial surface is the company's own pipeline.